Moreover, bosentan—an endothelin receptor antagonist that is used in clinical practice in the treatment of PAH, shows its anti-inflammatory effect by reducing the level of IL-6 and ICAM-1 in the blood, and this correlates with hemodynamic improvement [79]. The gene discussed is IL6; the disease is pulmonary arterial hypertension.